All In Biotech

Drug Trial Radar · NCT07766421

Evaluation of Iopofosine I 131 vs. R-CD in WM Patients

An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

219

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jan 2032

Study completion Jan 2035

Sponsor

Lead sponsor
Cellectar Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is: • Does iopofosine I 131 work better than R-CD when looking at the length of time during and after the treatment that a patient lives with WM but it does not get worse. Participants will: * Be randomly assigned to received either iopofosine I 131 or R-CD. * If assigned to iopofosine I 131, have it administered via infusion 2 times each cycle for a total of 2 cycles (each cycle is about 3 months long). * If assigned to R-CD, it will be administered for up to six cycles, and each cycle is 3-weeks long * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications.

Conditions

  • Waldenstrom Macroglobulinaemia
  • Waldenstrom Macroglobulinemia
  • Waldenstrom's Macroglobulinaemia Refractory
  • Waldenstrom Macroglobulinemia With Nodal Disease
  • Waldenstrom's Macroglobulinemia Recurrent

Interventions

  • Iopofosine I 131Drug

    Fractionated dose

  • Rituximab (active comparator)Drug

    Rituximab

  • CyclophosphamateDrug

    Cyclophosphamide

  • DexamethasoneDrug

    Dexamethasone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Superiority of progression free survival (PFS)Time frame: From baseline randomization through study completion of progressive disease, or death due to any reason (whichever status is recorded first).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.